Brief: G1 Therapeutics To Continue Phase 3 Trial Of Trilaciclib In Metastatic Triple Negative Breast Cancer

G1 Therapeutics

12/02/2024 22:02

Feb 12 (Reuters) - G1 Therapeutics Inc  GTHX.O :
    * G1 THERAPEUTICS TO CONTINUE PIVOTAL PHASE 3 TRIAL OF
TRILACICLIB
IN METASTATIC TRIPLE NEGATIVE BREAST CANCER FOLLOWING INTERIM
ANALYSIS BY INDEPENDENT DATA MONITORING COMMITTEE
    * G1 THERAPEUTICS INC - FINAL ANALYSIS EVALUATING OVERALL
SURVIVAL
(OS) IS ESTIMATED TO OCCUR IN Q3 OF 2024
    * G1 THERAPEUTICS INC: DMC DID NOT EXPRESS ANY CONCERNS
REGARDING
SAFETY OR RECOMMEND ANY OTHER CHANGES TO STUDY

Source text for Eikon:  ID:nGNX4TvYBl 
Further company coverage:  GTHX.O 

 ((reuters.briefs@thomsonreuters.com;))